LITS - Lite Strategy, Inc. Common Stock
| Day | 1m | 10m | 60m | PreMarket | Market | AfterHours | Gap |
|---|---|---|---|---|---|---|---|
| 2.21 -0.04 (-1.81%) | --- | --- | --- | -0.01 (-0.45%) | -0.12 (-5.13%) | 0.0 (0.0%) | 0.0 (0.0%) |
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor.
Category:
PHARMACEUTICAL PREPARATIONS
Market Period:
Closed
Earnings & Ratios
- Basic EPS:
- Diluted EPS:
- Basic P/E:
- Diluted P/E:
- RSI(14) 1m:
- 0.0
- VWAP:
- 2.17
- RVol:
Events
| Period | Kind | Movement | Occurred At |
|---|